Healthcare Industry News: X-ray imaging
News Release - October 14, 2015
Eclipse(TM) Treatment Planning Software from Varian Now Offers Robust Optimization and Proton Therapy Dose Calculation ToolsThe latest software release, including the Acuros® proton therapy algorithm for faster, more accurate dose calculation, receives FDA 510(k) clearance
PALO ALTO, Calif., Oct. 14, 2015 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (VAR) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the latest release of the company's Eclipse™ treatment planning software, which now incorporates the Acuros® PT advanced dose calculation algorithm for faster, more accurate proton therapy treatment planning.
Other enhancements to the Eclipse software include robust planning and optimization tools that enable proton treatment planners to account for uncertainties connected with patient setup error, tumor motion during treatment, as well as the heterogeneity of tissues surrounding the tumor. The new release also enables users to create scripts that expedite planning functions, quality assurance, data mining, and research.
The Acuros PT dose calculation algorithm is designed to improve the accuracy of the proton dose calculation, especially in regions of the body where the tissues vary in density such as the lung, where air, bone, and soft tissue are in close proximity. The algorithm also considers the density of the treatment accessories/beam shaping devices being used, and enables planning for treatment at the wide range of energies used depending on the depth of the tumor within the body. Proton planning in Eclipse using the Acuros PT algorithm takes significantly less time than was previously required using other methods.
"Acuros PT is the next innovation to come out of the acquisition of Transpire, Inc. last year," says Jeff Amacker, senior director of clinical solutions. "It brings the benefits of the sophisticated computing methods that Acuros imparted for conventional radiotherapy and brachytherapy to the world of proton planning."
Eclipse is the market leading radiotherapy treatment planning software, in use at some 3,400 cancer treatment centers worldwide. "These recent enhancements make it simpler, faster, and easier to use Eclipse to plan highly accurate proton therapy treatments using the same interface, in a software environment that interfaces seamlessly with Varian's ARIA® oncology information system—a platform that many Varian customers use to manage clinical and administrative processes in their cancer clinics," Amacker said.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit www.varian.com or follow us on Twitter.
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the ability of the company's technology and products to treat cancer or improve outcomes; and any statements using the terms "will," "can," "goal," "ongoing," "look forward to," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.